CIM Investment Management’s Pacific Biosciences PACB Stock Holding History

CIM Investment Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,301	Closed	-$23K	–	262
2025 Q4	$23K	Hold	12,301	–	–	0.01%	244
2025 Q3	$15.7K	Sell	12,301 -13,249	-52%	-$17.9K	﹤0.01%	247
2025 Q2	$39.4K	Buy	25,550 +12,822	+101%	+$14.8K	0.01%	251
2025 Q1	$15K	Sell	12,728 -303	-2%	-$465	﹤0.01%	238
2024 Q4	$23.8K	Hold	13,031	–	–	0.01%	247
2024 Q3	$22.2K	Hold	13,031	–	–	0.01%	253
2024 Q2	$17.9K	Sell	13,031 -3,106	-19%	-$6.27K	0.01%	255
2024 Q1	$60.5K	Hold	16,137	–	–	0.02%	279
2023 Q4	$158K	Hold	16,137	–	–	0.05%	273
2023 Q3	$135K	Hold	16,137	–	–	0.05%	265
2023 Q2	$215K	Hold	16,137	–	–	0.07%	240
2023 Q1	$187K	Buy	16,137 +555	+4%	+$5.52K	0.07%	246
2022 Q4	$127K	Hold	15,582	–	–	0.05%	232
2022 Q3	$90K	Hold	15,582	–	–	0.04%	213
2022 Q2	$69K	Hold	15,582	–	–	0.03%	226
2022 Q1	$142K	Buy	+15,582	New	+$179K	0.05%	243

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CIM Investment Management's PACB Position: Q1 2026 in Review

CIM Investment Management sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 12,301 shares — an estimated $23K sold.

CIM Investment Management first reported a position in PACB in Q1 2022 and held it in 16 quarters. The position peaked at $215K in Q2 2023. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

CIM Investment Management reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
CIM Investment Management sold 12,301 Pacific Biosciences shares in Q1 2026, an estimated $23K.
CIM Investment Management first reported a position in Pacific Biosciences in Q1 2022 and held it in 16 quarters.
CIM Investment Management's Pacific Biosciences position peaked at $215K in Q2 2023.
231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.